Comparison of in Vitro Activities of Gatifloxacin and Ciprofloxacin Against Four Taxa of Rapidly Growing Mycobacteria

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2002 Sep 18

PMID 12234861

Citations 8

Authors

Barbara A Brown-Elliott

Richard J Wallace Jr

Christopher J Crist

Linda Mann

Rebecca W Wilson

Affiliations

Soon will be listed here.

Abstract

By using current NCCLS broth microdilution methods, we found that gatifloxacin inhibited 90% of the isolates of the Mycobacterium fortuitum group at < or =0.12 micro g/ml and 90% of the Mycobacterium chelonae isolates at < or =4 micro g/ml. Gatifloxacin was generally fourfold more active than ciprofloxacin. We recommend that both gatifloxacin and ciprofloxacin be tested routinely against rapidly growing mycobacteria.

Citing Articles

Comparison of Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials against Isolates of Nontuberculous Mycobacteria.

Brown Elliott B, Wallace Jr R Antimicrob Agents Chemother. 2021; 65(7):e0007921.

PMID: 33846136 PMC: 8218650. DOI: 10.1128/AAC.00079-21.

Comparison of Two Commercial Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) Systems for Identification of Nontuberculous Mycobacteria.

Brown-Elliott B, Fritsche T, Olson B, Vasireddy S, Vasireddy R, Iakhiaeva E Am J Clin Pathol. 2019; 152(4):527-536.

PMID: 31314059 PMC: 6733354. DOI: 10.1093/ajcp/aqz073.

Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Brown-Elliott B, Nash K, Wallace Jr R Clin Microbiol Rev. 2012; 25(3):545-82.

PMID: 22763637 PMC: 3416486. DOI: 10.1128/CMR.05030-11.

In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

Disratthakit A, Doi N Antimicrob Agents Chemother. 2010; 54(6):2684-6.

PMID: 20368403 PMC: 2876381. DOI: 10.1128/AAC.01545-09.

In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.

Molina-Torres C, Ocampo-Candiani J, Rendon A, Pucci M, Vera-Cabrera L Antimicrob Agents Chemother. 2010; 54(5):2188-90.

PMID: 20231398 PMC: 2863650. DOI: 10.1128/AAC.01603-09.

References

Steingrube V, Gibson J, Brown B, Zhang Y, Wilson R, Rajagopalan M . PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria. J Clin Microbiol. 1995; 33(1):149-53. PMC: 227898. DOI: 10.1128/jcm.33.1.149-153.1995. View

Tebas P, Sultan F, Wallace Jr R, Fraser V . Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis. 1995; 20(2):443-4. DOI: 10.1093/clinids/20.2.443. View

Wallace Jr R, Meier A, Brown B, Zhang Y, Sander P, Onyi G . Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996; 40(7):1676-81. PMC: 163394. DOI: 10.1128/AAC.40.7.1676. View

Bauernfeind A . Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1998; 40(5):639-51. DOI: 10.1093/jac/40.5.639. View

Brown B, Springer B, Steingrube V, Wilson R, Pfyffer G, Garcia M . Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on.... Int J Syst Bacteriol. 1999; 49 Pt 4:1493-511. DOI: 10.1099/00207713-49-4-1493. View

Wallace Jr R, Brown-Elliott B, Ward S, Crist C, MANN L, Wilson R . Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001; 45(3):764-7. PMC: 90370. DOI: 10.1128/AAC.45.3.764-767.2001. View

Telenti A, Marchesi F, Balz M, Bally F, Bottger E, Bodmer T . Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol. 1993; 31(2):175-8. PMC: 262730. DOI: 10.1128/jcm.31.2.175-178.1993. View

Brown-Elliott B, Wallace Jr R, Blinkhorn R, Crist C, MANN L . Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis. 2001; 33(8):1433-4. DOI: 10.1086/322523. View

Wilson R, Steingrube V, Bottger E, Springer B, Brown-Elliott B, Vincent V . Mycobacterium immunogenum sp. nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks and contaminated metalworking fluids: an international cooperative study on mycobacterial taxonomy. Int J Syst Evol Microbiol. 2001; 51(Pt 5):1751-1764. DOI: 10.1099/00207713-51-5-1751. View

10.

Wallace Jr R, Bedsole G, Sumter G, Sanders C, Steele L, Brown B . Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother. 1990; 34(1):65-70. PMC: 171521. DOI: 10.1128/AAC.34.1.65. View

11.

Brown B, Wallace Jr R, Onyi G, De Rosas V, Wallace 3rd R . Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother. 1992; 36(1):180-4. PMC: 189249. DOI: 10.1128/AAC.36.1.180. View

12.

Wallace Jr R, Brown B, Onyi G . Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis. 1992; 166(2):405-12. DOI: 10.1093/infdis/166.2.405. View

13.

Jones R, Pfaller M . Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99). Diagn Microbiol Infect Dis. 2001; 39(4):237-43. DOI: 10.1016/s0732-8893(01)00229-2. View